Venmax Drugs merger vote: key Oct 2026 meeting details

NCLT sets the next procedural step

Venmax Drugs & Pharmaceuticals Ltd has scheduled an equity shareholders meeting on October 24, 2026 to consider and approve its proposed merger with Hatri Pharma Private Limited. The meeting is being convened following directions from the National Company Law Tribunal (NCLT), Hyderabad Bench-II. The tribunal’s order is dated September 7, 2026, and relates to a Scheme of Arrangement under the Companies Act, 2013. The merger involves Hatri Pharma Private Limited as the transferor company merging into Venmax Drugs & Pharmaceuticals Limited as the transferee company. For shareholders, the meeting is the key checkpoint where the scheme is placed for approval before subsequent regulatory steps. The company has indicated that the session will be conducted through video conferencing or other audio-visual means to enable remote participation. The registered office in Hyderabad is the stated venue for the meeting.

What shareholders are being asked to approve

The meeting is focused on the proposed amalgamation of Hatri Pharma Private Limited into Venmax Drugs & Pharmaceuticals Ltd. The NCLT has directed the listed company to convene the meeting specifically for this purpose. The scheme falls under Sections 230 and 232 of the Companies Act, 2013, read with Section 102, which govern compromises, arrangements, and required disclosures in shareholder communications. In practical terms, equity shareholders will be asked to vote on whether they accept the scheme as presented. The outcome is relevant because it determines whether the company can proceed to the next stages of the restructuring process. The tribunal direction reflects that the application related to the scheme has moved forward to the shareholder-consent stage. The company has not described any alternative proposals in the provided information.

Meeting date, time, and how it will be held

The NCLT Hyderabad Bench scheduled the meeting for Saturday, October 24, 2026, at 12:30 pm (IST). Venmax Drugs has stated it will be conducted through Video Conferencing (VC) or Other Audio Visual Means (OAVM). Although the meeting is virtual, the venue is specified as the registered office of the transferee company in Hyderabad, which is standard practice for convening meetings hosted electronically. The structure is intended to support shareholder access without requiring physical attendance. The company has also noted that notices are being sent electronically to shareholders whose email addresses are registered with the company or depositories. This aligns with the meeting’s VC/OAVM format. Shareholders are expected to rely on the official notice and statement for procedural details and voting instructions.

Where the notice and scheme documents can be accessed

Venmax Drugs has said shareholders can access the Notice and Statement issued under Sections 230 and 232 read with Section 102 of the Companies Act, 2013. The documents are available through multiple channels: the company’s website, the Bombay Stock Exchange (BSE) website, and the CDSL e-voting portal. This multi-platform availability is designed to ensure that shareholders receive the same set of disclosures and instructions. The company has also indicated that the notice is being sent electronically to eligible shareholders. Investors typically use the notice to review the scheme’s key terms, meeting process, and voting mechanics. Any further steps after shareholder approval would depend on the scheme process and regulatory workflow.

Share exchange ratio disclosed in the merger scheme

One disclosed term of the scheme is the proposed equity share exchange. Under the scheme, Hatri Pharma Private Limited’s 2.373 crore equity shares would be exchanged for an equal number of Venmax shares, subject to shareholder and subsequent regulatory approvals. This indicates a 1:1 exchange based on the number of Hatri shares referenced in the provided information. The share exchange is a central element because it determines how ownership in the listed company changes after the merger. The information provided does not include a valuation summary, fairness opinion details, or financial metrics for either entity. It also does not specify a record date for the exchange, which is usually addressed later in the process. Shareholders will therefore likely rely on the official scheme documents for fuller context.

Key facts at a glance

The NCLT order and case reference

The direction to convene the equity shareholders meeting came from NCLT Hyderabad. The information provided also references the case application as CA (CAA) 30/230/HDB/2026, which was allowed and disposed of on September 7, 2026. This is relevant because it signals that the tribunal has already considered the application to the extent necessary to order a shareholder meeting. For investors tracking corporate actions, the case reference helps identify the matter in filings and legal records. The tribunal’s role at this stage is procedural, ensuring that the company follows the prescribed process for seeking shareholder consent. The next steps, beyond this meeting, are described only generally as requiring further approvals. The company’s disclosures in the provided information focus mainly on meeting logistics and access to documents.

How this aligns with Venmax’s recent corporate calendar

Separately, Venmax Drugs & Pharmaceuticals approved its 37th Annual General Meeting (AGM) notice and certain director appointments during a board meeting on August 31, 2026. The company scheduled the AGM via video conferencing on September 26, 2026. It also disclosed a remote e-voting window for the AGM running from September 23 to September 25, 2026, with a cut-off date of September 18, 2026. The register of members and share transfer books were stated to remain closed from September 18 to September 26, 2026. M/s Kashinath Sahu & Co. was appointed as scrutinizer for the e-voting process. These disclosures indicate the company is using digital meeting and voting infrastructure across key shareholder events during the period.

Other disclosed board actions around the same period

The provided information also notes that Venkata Rao Sadhanala was appointed Managing Director with an annual pay of Rs 30 lakh. In another disclosure referenced, the board approved Q1 FY27 results and forfeited 7,80,001 warrants, retaining Rs 39,00,005. These items are separate from the merger vote but are part of the company’s recent corporate updates. They also indicate ongoing governance and capital-related actions alongside the merger process. The company’s schedule of meetings and disclosures suggests multiple shareholder-facing actions within a short timeframe. For investors, this makes it important to track notices and timelines closely across different events. The merger meeting on October 24, 2026 is distinct from the AGM and is tied directly to the NCLT process.

Market impact: what is confirmed and what is not

The confirmed market-relevant facts at this stage are procedural: a tribunal-directed shareholder meeting date, the virtual mode, and one disclosed exchange term involving 2.373 crore Hatri shares. The information provided does not quantify expected financial synergies, revenue impact, or operational changes, so those outcomes cannot be assessed from the disclosed details alone. Similarly, there is no disclosed timeline in the provided information for completion of the amalgamation beyond the shareholder and “subsequent regulatory approvals” condition. The availability of scheme documents on the company website, BSE website, and the CDSL portal provides a structured path for shareholders to review the proposal before voting. A reported reference in the provided text also states Venmax Drugs & Pharma share price as Rs 24, but no timestamp or session details are included alongside that figure. Investors typically watch how such corporate actions influence trading interest, but any price impact would need to be evaluated using market data around the disclosure and meeting dates.

Why the October 24 vote matters

Shareholder approval is a key gate in an NCLT-supervised merger process. Without an affirmative vote, the scheme cannot proceed in the form presented. The October 24, 2026 meeting therefore determines whether Venmax can move forward with the proposed amalgamation of Hatri Pharma into the listed entity. The disclosed share exchange quantity provides a starting point for shareholders to assess dilution and ownership change, though full evaluation would depend on the complete scheme documentation. The use of VC/OAVM and electronic dissemination of notices reflects the company’s approach to enabling participation without physical attendance. The next actionable step for shareholders is to review the notice and statement published through the official channels and be prepared for the meeting agenda. Any further developments would follow the formal sequence set by the Companies Act and the tribunal process.

Conclusion

Venmax Drugs & Pharmaceuticals Ltd will hold an NCLT-directed equity shareholders meeting on October 24, 2026 at 12:30 pm (IST) via VC/OAVM to vote on the merger scheme with Hatri Pharma Private Limited. The direction stems from an NCLT Hyderabad Bench-II order dated September 7, 2026. Shareholders can access the notice and statutory statement through the company website, BSE website, and the CDSL e-voting portal, with notices also being sent electronically to registered email IDs. The next confirmed milestone is the meeting itself, after which the process would move to subsequent approvals as applicable under the scheme and regulatory framework.